Abstract
Objective
To evaluate the performance characteristics of AJCC 7th and 8th staging systems among patients with adrenal cortical carcinoma.
Methods
Surveillance, Epidemiology, and End Results (SEER) 18-registry was accessed and patients with adrenocortical carcinoma who were diagnosed 2010–2015 with complete information about AJCC 7th staging system were included. AJCC 8th staging system information was then reconstructed for each patient using available TNM staging variables. Kaplan–Meier overall survival estimates, multivariable Cox regression analysis, and concordance index (C-statistic) were used to examine the performance characteristics of both staging systems.
Results
A total of 574 patients with a diagnosis of adrenocortical carcinoma were included in the current analysis. Using Kaplan–Meier survival estimates, overall survival was compared among different AJCC stages for both versions; and the P value was significant (< 0.001) for both comparisons. C-statistic was then calculated for both staging systems and the results were as follows: for AJCC 7th version: 0.726 (95% CI 0.683–0.769); and for AJCC 8th version: 0.745 (95% CI 0.704–0.786). Patients with M1 disease (stage IV according to AJCC 8th edition) were then divided according to the extent of distant metastases into single versus multiple sites of metastases. Using Kaplan–Meier survival estimates, patients with a single site of metastases have better overall survival (P = 0.006). A C-statistic for a hypothetical modification of AJCC 8th staging system subdividing stage IV patients into IVA and IVB based on the number of metastatic sites was: 0.753 (95% CI 0.713–0.794).
Conclusions
There is a minimal difference in the prognostic performance between both versions of the AJCC staging system. Subdivision of stage IV cancer into stage IVA and IVB (according to the number of organs with metastatic deposits) should be considered in subsequent versions of adrenocortical carcinoma staging.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM et al (2014) Adrenocortical carcinoma. Endocr Rev 35(2):282–326
Fassnacht M, Kroiss M, Allolio B (2013) Update in adrenocortical carcinoma. J Clin Endocrinol Metab 98(12):4551–4564
Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R et al (2018) European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 179(4):G1-g46
Owen DH, Patel S, Wei L, Phay JE, Shirley LA, Kirschner LS et al (2019) Metastatic adrenocortical carcinoma: a single institutional experience. Horm Cancer 10(4–6):161–167
Papotti M, Libè R, Duregon E, Volante M, Bertherat J, Tissier F (2011) The Weiss score and beyond–histopathology for adrenocortical carcinoma. Horm Cancer 2(6):333–340
Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T et al (2015) Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European network for the study of adrenal tumor (ENSAT) study. Ann Oncol 26(10):2119–2125
DeLellis RA (2004) Pathology and genetics of tumours of endocrine organs. IARC
Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F et al (2009) Limited prognostic value of the 2004 International Union against cancer staging classification for adrenocortical carcinoma. Cancer 115(2):243–250
Amin MB, Edge SB (2017) AJCC cancer staging manual. Springer
Surveillance, Epidemiology, and End Results (SEER) Program (2020) SEER*Stat Database: incidence—SEER research data, 18 registries, Nov 2019 sub (2000–2017)—linked to county attributes—time dependent (1990–2017) income/rurality, 1969–2018 counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission. Available at: www.seer.cancer.gov. Accessed 24 Nov 2020
Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1476–1490
Vaidya A, Nehs M, Kilbridge K (2019) Treatment of adrenocortical carcinoma. Surg Pathol Clin 12(4):997–1006
Abdel-Rahman O (2018) Validation of American joint committee on cancer eighth staging system among prostate cancer patients treated with radical prostatectomy. Ther Adv Urol 10(2):35–42
Abdel-Rahman O (2018) Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat 168(1):269–275
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Advisory board; Eisai Canada, Lilly Canada, and Roche Canada.
Informed consent
As this study is based on a publicly available database without identifying patient information, informed consent was not needed.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
40618_2021_1618_MOESM1_ESM.jpg
Supplementary file1 (JPG 39 KB) Supplementary figure 1: Kaplan-Meier curve for the overall survival according to extent of metastatic disease (among patients with M1 disease)
Rights and permissions
About this article
Cite this article
Abdel-Rahman, O. Revisiting the AJCC staging system of adrenocortical carcinoma. J Endocrinol Invest 45, 89–94 (2022). https://doi.org/10.1007/s40618-021-01618-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-021-01618-0